Skip to content
Learn More


iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming

December 16, 2019

Presentation Demonstrates Advantages of iBio’s Recently Launched FastGlycaneering Development Service™ – NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) presented results of the application of its new FastGlycaneering Development Service℠ to enhance potency of recombinant proteins at last week’s Antibody Engineering & Therapeutics conference in San Diego, CA. Specifically, the presented data demonstrated  the ability to …

Read More

iBio Introduces FastGlycaneering Development Service℠ to Power Recombinant Protein Production

December 10, 2019

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today unveiled the FastGlycaneering Development Service℠, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Biopharmaceutical innovators and biosimilar producers will now be able to take advantage of low-cost afucosylation controls, oligomannose modification capabilities, and more custom glycosylation techniques using iBio’s …

Read More

iBio Joins Manufacturing USA’s Tissue Biofabrication Initiative

December 3, 2019

iBio to Support the 3D Bioprinting Industry with Enabling Biomaterials NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it is now part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (“ARMI”). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA Institute. ARMI brings …

Read More

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

September 18, 2019

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”). Following iBio’s successful use of its technologies and manufacturing capabilities to advance the development …

Read More

iBio and CC-Pharming Expand Business Collaboration in China

August 27, 2019

iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (“iBio Rituximab”) product candidates for the territory of China. In addition, the Company will grant to CC-Pharming a research license to iBio’s FastPharming™ System and know-how …

Read More